Get this report today!
Table of Contents
Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide high specificity to treat tumors and several formats exist for the types of cancer monoclonal antibodies available.
According to “Cancer Monoclonal Antibodies Market to 2015”, cancer monoclonal antibodies have evolved greatly from the first time they were implemented, and have created a strong demand since then. In the recent time, some very important monoclonal antibodies, such as Yervoy (ipilimumab) have entered the market. Our study expects that these antibodies will consume the share of leading monoclonal antibody products in the coming years.
Our research observed that the strong demand for effective cancer treatments and high prevalence are driving the cancer monoclonal antibodies market which is anticipated to grow at a CAGR of around 7% during 2012-2015. While research and innovation in this field have been growing exorbitantly, the industry has witnessed a large number of consolidation activities. In the report, we have also studied how technological advancements and a subsequent increase in number of approvals are influencing the market growth.
During the study of latest industry trends and drivers, we observed that conjugated cancer antibody therapies offer efficient cancer treatments. Besides, bispecific antibodies (BiAbs) present a unique opportunity to redirect immune effector cells to kill cancer cells. Our report covers the analysis of the entire monoclonal antibody market for cancer, and presents market forecasts for leading products. The geographic analyses for key markets, carried out in the research, foresee that the US and Europe will continue holding significant market shares, and
Japan will exhibit unaltered double digit growth.
In our research report, we have conducted a comprehensive pipeline analysis of the expected cancer monoclonal antibodies and their phase of development. We found that maximum products are expected in the field of breast cancer in near future. The study discusses in detail the key market players, their business activities, key monoclonal antibody products which are available in the market and in pipeline. Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years.
Talk to Louis
+1 718 618 4302
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
World demand to increase 6.4% annually through 2017 World enzyme demand is forecast to rise 6.4 percent per annum to $6.9 billion in 2017. Increasing per capita incomes in developing countries will help ...
Biosimilars are therapeutically similar copies of biologic drugs. The European Medicines Agency (EMA) defines biosimilars as drugs that claim to be “similar” to their reference biological medicinal ...
TechNavio's analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing numbe ...
... Of anti-ige antibody annually. The process is similar to other systems except for initial corn milling and protein extraction. The relative low recovery is come from protein lost during milling. Furthermore ...
... As a cand to be used in a subunit vaccine against swine erysipelas (imada et al. 1999; Kitajima et al. 2000), Replacing the cellular vaccines in use. The production of recombinant antigenic proteins ...
... Konstantinov kb, yoshida t: dielectric measurement to monitor the growth and the physiological states of biological cells. bioprocess engineering 1994, 11:213 222. 40. Luli gw, strohl wr: comparison of growth ...
Reportlinker.com © Copyright 2014. All rights reserved.